Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ceftriaxone + sulbactam (Suncure Lifescience)
- Development stage
- Unknown
- Lead developer
- Suncure Lifescience
- Modality
- Small Molecules
- Administration
- Intramuscular, Intravenous
01
Overview
**Cefzoxin** is Suncure Lifescience's injectable fixed-dose antibacterial combination of **ceftriaxone 1 g** and **sulbactam 500 mg**. Ceftriaxone is a third-generation cephalosporin that binds bacterial penicillin-binding proteins and inhibits cell-wall synthesis. Sulbactam is an irreversible beta-lactamase inhibitor that protects ceftriaxone from enzymatic degradation by susceptible beta-lactamase-producing bacteria. The product is marketed for treatment of bacterial infections.
- Brand names
- CefzoxinCefzoxin-SB
02
Targets
β-lactamasePBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on ceftriaxone + sulbactam (Suncure Lifescience).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ceftriaxone + sulbactam (Suncure Lifescience).